Crossmark

Growth hormone therapy promotes bone growth in idiopathic short stature children by activating the IGF-1 pathway via IGFBP2-mediated inhibition of THBS1

Crossref DOI link: https://doi.org/10.1007/s11626-025-01118-y

Published Online: 2025-11-05

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Haiyan

Zhao, Qin
Funding

Funding for this research was provided by:

Chinese International Medical Exchange Foundation
License Information

Text and Data Mining valid from 2025-11-05

Version of Record valid from 2025-11-05
More Information

Article History

Received: 26 June 2025

Accepted: 8 September 2025

First Online: 5 November 2025

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no conflicts of interest to report regarding the present study.

Document is current

Any future updates will be listed below